What do weapons and drug discovery have in common?
Over the last 24 hours, billions of dollars and a lead investor. In quick succession, Demis Hassabis’s Isomorphic Labs announced it had raised a $2.1 billion Series B, and very early today, Anduril announced it had closed its $5 billion Series H at a $61 billion valuation. (Thrive Capital led in both rounds, and Andreessen Horowitz additionally led for Anduril.)
I have an admittedly odd vantage point here: Two of the biggest features of my career to date have involved me spending a lot of time with Anduril and Isomorphic, respectively, a defense tech company and an AI drug discovery company. And though I will under no circumstances tell you they are the same (building drones and searching for cancer cures have wildly different financial and ethical landscapes), they also have a few things in common.
Both Anduril and Isomorphic are deeply technical companies that have risen at a time when advances in AI have not only rend
We współpracy z: https://fortune.com/2026/05/13/isomorphic-anduril-thrive-raise/
